Top

BMC Pulmonary Medicine

Published in:

Open Access 01-12-2024 | Mepolizumab | Research

Monoclonal antibodies in idiopathic chronic eosinophilic pneumonia: a scoping review

Authors: Andrea Dionelly Murillo, Ana Isabel Castrillon, Carlos Daniel Serrano, Liliana Fernandez-Trujillo

Published in: BMC Pulmonary Medicine | Issue 1/2024

Abstract

Background

Idiopathic chronic eosinophilic pneumonia (ICEP) is a rare disease characterized by pulmonary radiological alterations, peripheral eosinophilia, and demonstrated pulmonary eosinophilia. Oral steroids (OSs) are the standard management, but relapses occur in up to 50% of patients during the decrease or suspension of steroids, usually requiring reinitiation of treatment, exposing patients to secondary events derived from the management. Management with monoclonal antibodies has been proposed in these cases to control the disease and limit the secondary effects. The objective is to describe the extent and type of evidence regarding the use of monoclonal antibodies for ICEP.

Methods

A panoramic review of the literature was performed. Observational and experimental studies of pediatric and adult populations that managed recurrent ICEP with monoclonal antibodies were included. Data search, selection, and extraction were performed by two independent reviewers.

Results

937 studies were found. After applying the inclusion and exclusion criteria, 37 titles remained for the final analysis: a retrospective, observational, real-life study, two case series publications, and 34 case reports published in academic poster sessions and letters to the editor. In general, the use of monoclonal antibodies approved for severe asthma could be useful for the control of ICEP, since most of the results show a good response for clinical and radiological outcomes. Biological drugs seem to be a safer option for controlling relapses in ICEP, allowing lowering/suspension of OSs, and sometimes replacing them in patients intolerant to them, patients with significant comorbidities, and patients who have already developed adverse events.

Conclusion

The extent of the evidence supporting management of ICEP with monoclonal antibodies against IL-5 and IgE (omalizumab) is limited, but it could be promising in patients who present frequent relapses, in cortico-dependent individuals, or in patients in whom the use of steroids is contraindicated. The extent of the evidence for management with dupilumab is more limited. Studies with better design and structure are needed to evaluate quality of life and outcomes during a clear follow-up period. To our knowledge, this is the first scoping review of the literature showing the extent of the evidence for the management of ICEP with monoclonal antibodies.

Pahal P, Penmetsa GK, Modi P, Sharma S. Stat Pearls - NCBI Bookshelf: Eosinophilic Pneumonia. 2022.

Allen J, Wert M. Eosinophilic pneumonias. Journal of Allergy and Clinical Immunology. In Practice. 2018;6(5):1455–61. https://doi.org/10.1016/j.jaip.2018.03.011.CrossRefPubMed

Suzuki Y, Suda T. Eosinophilic pneumonia: a review of the previous literature, causes, diagnosis, and management. Allergology Int. 2019;68(4):413–9. https://doi.org/10.1016/j.alit.2019.05.006.CrossRef

Rosenberg CE, Khoury P. Approach to Eosinophilia presenting with pulmonary symptoms. Chest. 2021;159(2):507–16. https://doi.org/10.1016/j.chest.2020.09.247.CrossRefPubMed

Crowe M, Robinson D, Sagar M, Chen L, Ghamande S. Chronic eosinophilic pneumonia: clinical perspectives. Ther Clin Risk Manag. 2019;15:397–403. https://doi.org/10.2147/TCRM.S157882.CrossRefPubMedPubMedCentral

Asano K, Suzuki Y, Tanaka J, Kobayashi K, Kamide Y. Treatments of refractory eosinophilic lung diseases with biologics. Allergology Int. 2022. https://doi.org/10.1016/j.alit.2022.10.004.

Suzuki Y, Oyama Y, Hozumi H, Imokawa S, Toyoshima M, Yokomura K, Nakamura H, Kuroishi S, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Koshimizu N, Yamada T, Mori K, Masuda M, Shirai T, Suda T. Persistent impairment on spirometry in chronic eosinophilic pneumonia: a longitudinal observation study (Shizuoka-CEP study). Ann Allergy Asthma Immunol. 2017;119(5):422-428e2. https://doi.org/10.1016/j.anai.2017.08.009.CrossRefPubMed

Suzuki Y, Suda T. Long-term management and persistent impairment of pulmonary function in chronic eosinophilic pneumonia: a review of the previous literature. Allergology Int. 2018;67(3):334–40. https://doi.org/10.1016/j.alit.2017.12.004.CrossRef

Giovannini-Chami L, Blanc S, Hadchouel A, Baruchel A, Boukari R, Dubus JC, Fayon M, Le Bourgeois M, Nathan N, Albertini M, Clément A, De Blic J. Eosinophilic pneumonias in children: a review of the epidemiology, diagnosis, and treatment. Pediatr Pulmonol. 2016;51(2):203–16. https://doi.org/10.1002/ppul.23368.CrossRefPubMed

10.

Cottin V. Eosinophilic Lung diseases. Clin Chest Med. 2016;37(3):535–56. https://doi.org/10.1016/j.ccm.2016.04.015.CrossRefPubMed

11.

Couture J, Adri D, Villegas JM. Eosinofilias Pulmonares: Hallazgos que un radiólogo debe conocer Pulmonary Eosinophilias: Findings that a Radiologist Should Know. 2019;113–120.

12.

Gómez-Bastero Fernández AP, Pacheco VA, Valido Morales AS. No es asma todo lo que parece: eosinofilias pulmonares. Revista Asma. 2017;2(1):29–39.

13.

Oyama Y, Fujisawa T, Hashimoto D, Enomoto N, Nakamura Y, Inui N, Kuroishi S, Yokomura K, Toyoshima M, Yamada T, Shirai T, Masuda M, Yasuda K, Hayakawa H, Chida K, Suda T. Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia. Eur Respir J. 2015;45(6):1624–31. https://doi.org/10.1183/09031936.00199614.CrossRefPubMed

14.

Pitlick MM, Li JT, Pongdee T. Current and emerging biologic therapies targeting eosinophilic disorders. World Allergy Organ J. 2022;15(8):100676. https://doi.org/10.1016/j.waojou.2022.100676.CrossRefPubMedPubMedCentral

15.

Delcros Q, Groh M, Nasser M, Kahn JE, Cottin V. Steroid alternatives for managing eosinophilic lung diseases. Expert Opin Orphan Drugs. 2021;9(7–10):205–18. https://doi.org/10.1080/21678707.2021.2003777.CrossRef

16.

Agache I, Akdis CA, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Chu DK, Giacco D, Eiwegger S, Flood T, Firinu B, Gern D, Hamelmann JE, Hanania E, Hernández-Martín N, Knibb I, Mäkelä R, Nair M, Jutel P, M. EAACI biologicals guidelines—recommendations for severe asthma. Allergy: Eur J Allergy Clin Immunol. 2021;76(1):14–44. https://doi.org/10.1111/all.14425.CrossRef

17.

Svenningsen S, Kjarsgaard M, Zhang K, et al. Effect of dupilumab on sputum eosinophils in patients with moderate-to-severe asthma. Allergy: Eur J Allergy Clin Immunol Published Online. 2023. https://doi.org/10.1111/all.15901.CrossRef

18.

Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol Theory Pract. 2005;8:19–32.CrossRef

19.

Brenard E, Pilette C, Dahlqvist C, Colinet B, Schleich F, Roufosse F, Froidure A. Real-life study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia. Lung. 2020;198(2):355–60. https://doi.org/10.1007/s00408-020-00336-3.CrossRefPubMed

20.

Askin C, Morris M. When steroids fail: a population-based review of biologic therapies in the management of recalcitrant eosinophilic pneumonia. CHEST. Ann Meet Orig Investigations. 2021;160(4):A1273. https://doi.org/10.1016/j.chest.2021.07.1160.

21.

Tashiro H, Takahashi K, Kurihara Y, Sadamatsu H, Kuwahara Y, Kimura S, Sueoka-Aragane N. Anti-IL-5 agents for the treatment of idiopathic chronic eosinophilic pneumonia: a Case Series. J Asthma Allergy. 2022;15:169–77. https://doi.org/10.2147/JAA.S343272.CrossRefPubMedPubMedCentral

22.

David Y, Ben, Bentur L, Gur M, David BEN. Reverse butterfly pattern image with eosinophilia: effective treatment with benralizumab — a case report. 2021;1–4. https://doi.org/10.1002/ppul.25511.

23.

Izumo T, Kuse N, Awano N, Tone M, Jo T, Yoshimura H, Minami J, Takada K, Muto Y, Fujimoto K. Respiratory Medicine Case Reports Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia. Respiratory Med Case Rep. 2020;30:101062. https://doi.org/10.1016/j.rmcr.2020.101062.CrossRef

24.

Isomoto K, Baba T, Sekine A, Aiko N, Ogura T. Promising effects of Benralizumab on Chronic Eosinophilic Pneumonia. Intern Med Japanese Soc Intern Med. 2020;1195–8. https://doi.org/10.2169/internalmedicine.3606-19.

25.

Izhakian S, Pertzov B, Rosengarten D, Kramer MR. Successful treatment of acute relapse of chronic eosinophilic pneumonia with benralizumab and without corticosteroids: A case report. World J Clin Cases. 2022;10(18):6105–09.

26.

Angeletti G, Mazzolini M, Rocca A. Two years follow-up of relapsing eosinophilic pneumonia with concomitant severe asthma successfully treated with benralizumab: a case report and brief review of the literature. Respiratory Med Case Rep. 2022;41(December 2022):101795. https://doi.org/10.1016/j.rmcr.2022.101795.CrossRef

27.

Takano T, Inutsuka Y, Nakamura S, Ando N, Komori M. Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection. Official Case Reports Journal of the Asian Pacific Society of Respirology. 2021;9:9–11. https://doi.org/10.1002/rcr2.810.CrossRef

28.

Ricketti PA, Ricketti AJ. Relapsing chronic eosinophilic pneumonia treated successfully with benralizumab. Annals of Allergy Asthma and Immunology. 2021;126(6):726–7. https://doi.org/10.1016/j.anai.2021.02.016.CrossRef

29.

Yazawa S, Toyoshima M, Koda K, Suda T. Benralizumab as initial treatment for chronic eosinophilic pneumonia. Allergology Int. 2021;70:2020–2. https://doi.org/10.1016/j.alit.2020.07.005.CrossRef

30.

Braga S, Ribeiro J, Oliveira M, Silva JM, Reis M, Ferreira L. Eosinophilic pneumonia when steroids are not the answer: Case report. Chest. 2020;157(6):A174. https://doi.org/10.1016/j.chest.2020.05.195.CrossRef

31.

Garcia-Saucedo J, Carrillo-Martin I, Sanchez-Valenzuela M, Motoa G, Lee A, Gonzalez-Estrada A. Benralizumab for unresponsive steroid-dependent chronic eosinophilic pneumonia. Annals of Allergy Asthma & Immunology: Medically Challenging Cases Abstracts. 2019;123(5):134. https://doi.org/10.1016/j.anai.2019.08.436.CrossRef

32.

Shimizu Y, Kurosawa M, Sutoh Y, Sutoh E. Long-term treatment with Anti-interleukin 5 antibodies in a patient with chronic eosinophilic pneumonia. J Investig Allergol Clin Immunol. 2020;1:2018–9. https://doi.org/10.18176/jiaci.0468.CrossRef

33.

Sarkis E, Patel S, Burns K, Batarseh H, Jeffery M, Burns K, Batarseh H. Anti-interleukin (IL) -5 as a steroid-sparing agent in chronic eosinophilic pneumonia. J Asthma. 2020;57(1):82–6. https://doi.org/10.1080/02770903.2018.1543434.CrossRefPubMed

34.

Otoshi R, Baba T, Komatsu S, Asaoka M, Hagiwara E, Ogura T. Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty. Official Case Reports Journal of the Asian Pacific Society of Respirology. 2020;8:1–4. https://doi.org/10.1002/rcr2.514.CrossRef

35.

Mckillion P, Shrestha S, Abdullah A, Penupolu S, Medicine I. Chronic eosinophilic pneumonia: when corticosteroids are not enough. ATS Journal. Thematic Poster Session; 2021.

36.

Cyca P, Walker BL, Mitchell P, Weatherald J. Successful use of Mepolizumab for Steroid-Dependent Chronic Eosinophilic Pneumonia. J Respir Crit Care Med. Poster Sesion, C: Case Report; 2022.

37.

Eldaabossi SAM, Awad A, Anshasi N. Mepolizumab and dupilumab as a replacement to systemic glucocorticoids for the treatment of chronic eosinophilic pneumonia and allergic bronchopulmonary aspergillosis - case series, Almoosa specialist hospital. Respiratory Med Case Rep. 2021;34(October):101520. https://doi.org/10.1016/j.rmcr.2021.101520.CrossRef

38.

Benipal J, Harish A. Mepolizumab: a steroid alternative for chronic eosinophilic pneumonia. Annals of Allergy Asthma and Immunology. 2021;127(5):S87. https://doi.org/10.1016/j.anai.2021.08.271. Abstracts: Medically Challenging Cases/.CrossRef

39.

Sato H, Miyata Y, Inoue H, Tanaka A, Sagara H. Efficacy of Mepolizumab Extended interval dosing for 2 asthmatic patients with chronic eosinophilic pneumonia. J Investig Allergol Clin Immunol. 2021;459–60. https://doi.org/10.18176/jiaci.0671.

40.

Kisling A, Jones J, Hixson C, Fcap DO, Hostler D, Facp MPH, Facp JH. Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance. Drugs in Context Case Report. 2020;5–11. https://doi.org/10.7573/dic.2020-5-3.

41.

Askin C, Sjulin T. Steroid dependent chronic eosinophilic pneumonia: a win for il-5 antagnonism in an active duty service member. CHEST Fellow Case Report Posters. 2020;158(4):A1100. https://doi.org/10.1016/j.chest.2020.08.1010.CrossRef

42.

Ciuffreda M, Caruso C, Romano A, Sarni A. Effect of mepolizumab alone in chronic eosinophilic pneumonia relapse: a case report. J Allergy Clin Immunol Pract. 2020;8(10):3640–2. https://doi.org/10.1016/j.jaip.2020.06.053.CrossRefPubMed

43.

Jones J, Hostler D, Hostler J. Beyond steroids: mepolizumab for chronic eosinophilic pneumonia case report semifinalists 6. CHEST Case Report. 2019;156(4):A72. https://doi.org/10.1016/j.chest.2019.08.165.CrossRef

44.

Mcinnis I, Ms DO, Ferraro D. Singling out the eosinophil: successful treatment of refractory chronic. Chest. 2019;156(4):A1318. https://doi.org/10.1016/j.chest.2019.08.1182.CrossRef

45.

Mendes A, Pereira I, Ladeira I, Campainha S, Lima R, Fernandes A, June. 376–853. https://doi.org/10.1111/all.13961.

46.

Tomyo F, Sugimoto N. Anti-interleukin 5 antibody is effective for not only severe asthma and eosinophilic pneumonia but also eosinophilic bronchiolitis. J Asian Pac Soc Respirol Respirol Case Rep. 2019;7:1–4. https://doi.org/10.1002/rcr2.397.CrossRef

47.

Lawrence R, Klings ES. Management of Chronic Eosinophilic Pneumonia with Mepolizumab. ATS Journal. Thematic Poster Session, 2019;A1522–A1522. https://doi.org/10.1164/ajrccm-conference.2019.199.1_meeting_abstracts.a1522.

48.

To M, Kono Y, Yamawaki S, Soeda S, Katsube O, Kishi H, To Y. A case of chronic eosinophilic pneumonia successfully treated with mepolizumab. J Allergy Clin Immunol Pract. 2018;6(5):1746–1748e1. https://doi.org/10.1016/j.jaip.2018.06.017.CrossRefPubMed

49.

Lin RY, Santiago TP, Patel NM, Lin RY, Santiago TP, Patel NM, Lin RY, Santiago TP. Favorable response to asthma-dosed subcutaneous mepolizumab in eosinophilic pneumonia eosinophilic pneumonia. J Asthma. 2019;56(11):1193–7. https://doi.org/10.1080/02770903.2018.1534966.CrossRefPubMed

50.

Shin YS, Jin HJ, Nam YH, Ye Y. Successful treatment of chronic eosinophilic pneumonia with Anti-IgE therapy. J Korean Med Sci Case Rep. 2012;1261–4. https://doi.org/10.3346/jkms.2012.27.10.1261.

51.

Nehme R, Samaha D, Al Y. A case of relapsing chronic eosinophilic pneumonia treated by Omalizumab. Respiratory Med Case Rep. 2022;41(December 2022):101796. https://doi.org/10.1016/j.rmcr.2022.101796.CrossRef

52.

Laviña Soriano E, López AA, Alonso JLI. Response to Omalizumab in a Patient With Chronic Eosinophilic Pneumonia and Poor Response to Corticosteroids. Archivos de Bronconeumologia, SEPAR, 2017;10–11. https://doi.org/10.1016/j.arbres.2017.11.009.

53.

Kaya H, Tozkoparan E. Omalizumab as a steroid-sparing Agent in Chronic Eosinophilic. Chest. 2012;11:316–8. https://doi.org/10.1378/chest.11-1881.CrossRef

54.

Domingo C, Pomares X. Can Omalizumab B Effective in Chronic Eosinophilic Pneumonia? CHEST. To the Editor. 2013;143(1):274. https://doi.org/10.1378/chest.12-2035.CrossRef

55.

Fowler C. Dupilumab for chronic eosinophilic pneumonia. Pediatr Pulmonol. 2020;3229–30. https://doi.org/10.1002/ppul.25096. Letter to the Editor.

56.

Wechsler ME, Klion AD, Paggiaro P et al. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. Journal of Allergy and Clinical Immunology: In Practice. 2022;10(10):2695–2709. https://doi.org/10.1016/j.jaip.2022.05.019.

57.

Gharaibeh K, Alsaid H, Robinett S, Cowan KJ, M., Sachdeva A. Dupilumab-Induced severe Hypereosinophilia Complicated with Eosinophilic Pneumonia. Chest. 2022;162(4):A1276–7. https://doi.org/10.1016/j.chest.2022.08.1020.CrossRef

58.

Frohlich M, Olivenstein R, Cormier M. Eosinophilic pulmonary complications of dupilumab in 2 patients with asthma and chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunology: Pract. 2022;10(2):617–9. https://doi.org/10.1016/j.jaip.2021.11.029.CrossRef

59.

Kurihara M, Masaki K, Matsuyama E, Fujioka M, Hayashi R, Tomiyasu S, Sasahara K, Sunata K, Asaoka M, Akiyama Y, Nishie M, Irie M, Tanosaki T, Kabata H, Fukunaga K. How Can Dupilumab Cause Eosinophilic Pneumonia? Biomolecules. 2022;12(12):1–6. https://doi.org/10.3390/biom12121743.CrossRef

60.

Nishiyama Y, Koya T, Nagano K, Abe S, Kimura Y, Shima K, Toyama-Kosaka M, Hasegawa T, Sasaki T, Shinbori K, Ueki S, Takamura K, Kikuchi T. Two cases of dupilumab-associated eosinophilic pneumonia in asthma with eosinophilic chronic rhinosinusitis: IL-5-driven pathology? Allergology Int. 2022;71(4):548–51. https://doi.org/10.1016/j.alit.2022.03.005.CrossRef

Title: Monoclonal antibodies in idiopathic chronic eosinophilic pneumonia: a scoping review
Authors: Andrea Dionelly Murillo
Ana Isabel Castrillon
Carlos Daniel Serrano
Liliana Fernandez-Trujillo
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Mepolizumab
Pneumonia
Bronchial Asthma
Omalizumab
Eosinophilia
Dupilumab
Reslizumab
Published in: BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-024-02868-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Genomic features of lung cancer patients in Indonesia’s national cancer center

NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma

Prevalence, risk factors, and clinical characteristics of pulmonary embolism in patients with acute exacerbation of COPD in Plateau regions: a prospective cohort study

Isolated respiratory tract microorganisms and clinical characteristics in asthma exacerbation of obese patients: a multicenter study

Diagnosis model of early Pneumocystis jirovecii pneumonia based on convolutional neural network: a comparison with traditional PCR diagnostic method

Extracorporeal membrane oxygenation (ECMO) in patients with tuberculosis: systematic review and meta-analysis of 43 cases

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials